sars-cov-2 protein subunit recombinant vaccine PT Biopharma

Vaccineexperimental

Clinical trial activity

7 trials · 9 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
6
Phase 3
3
Phase 4
0

Earliest trial started Nov 30, 2021 (NCT05067894)

Timeline

2020s

  1. Jan 1, 2021

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2022

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2022

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05933278Phase 2Jul 31, 2023Diponegoro University, PT Bio Farma
NCT05727215Phase 2Feb 28, 2023Padjadjaran University, PT Bio Farma
NCT05546502Phase 3Oct 9, 2022PT Bio Farma, Universitas Gadjah Mada, University of Andalas, University of Indonesia
NCT05525208Phase 2Sep 1, 2022Padjadjaran University, PT Bio Farma, Udayana University
NCT05433285Phase 3Jun 7, 2022Diponegoro University, PT Bio Farma, Universitas Hassanudin, University of Andalas, University of Indonesia
NCT05313035Phase 2/Phase 3 (Phase 3)Apr 13, 2022Diponegoro University, PT Bio Farma, Universitas Hassanudin, University of Andalas, University of Indonesia
NCT05067894Phase 1/Phase 2 (Phase 2)Nov 30, 2021Government of Indonesia, PT Bio Farma, University of Indonesia
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
PT Bio FarmaFor profit7722021
University of IndonesiaAcademic/Hospital4022021
Diponegoro UniversityAcademic/Hospital3022022
University of AndalasAcademic/Hospital3012022
Padjadjaran UniversityAcademic/Hospital2012022
Universitas HassanudinAcademic/Hospital2012022
Government of IndonesiaGovernment1012021
Udayana UniversityAcademic/Hospital1012022
Universitas Gadjah MadaAcademic/Hospital1012022
9 organizations
Page 1 / 1